DBCFI-Artículos, capítulos...http://hdl.handle.net/10396/22742024-03-29T07:23:50Z2024-03-29T07:23:50ZObjective Assessment of Equine Locomotor Symmetry Using an Inertial Sensor System and Artificial Intelligence: A Comparative StudyCalle González, NatalieLo Feudo, Chiara MariaFerrucci, FrancescoRequena, F.Stucchi, LucaMuñoz, Anahttp://hdl.handle.net/10396/276962024-03-19T03:01:04Z2024-01-01T00:00:00ZObjective Assessment of Equine Locomotor Symmetry Using an Inertial Sensor System and Artificial Intelligence: A Comparative Study
Calle González, Natalie; Lo Feudo, Chiara Maria; Ferrucci, Francesco; Requena, F.; Stucchi, Luca; Muñoz, Ana
In horses, quantitative assessment of gait parameters, as with the use of inertial measurement units (IMUs) systems, might help in the decision-making process. However, it requires financial investment, is time-consuming, and lacks accuracy if displaced. An innovative artificial intelligence marker-less motion tracking system (AI-MTS) may overcome these limitations in the field. Our aim was to compare the level of agreement and accuracy between both systems and visual clinical assessment. Twenty horses underwent locomotion analysis by visual assessment, IMUs, and AI-MTS systems, under the following conditions: straight hard (SH), straight soft (SS), left and right circle hard (LCH, RCH), and soft (LCS, RCS). A greater number of horses were considered sound by clinical examination, compared to those identified as symmetric by the two gait analysis systems. More limbs were considered asymmetric by the AI-MTS compared to IMUs, suggesting its greater sensitivity. The greatest agreement between the two systems was found for the difference between two minima in vertical head position in SH, while the lowest for the difference between two minima in vertical pelvis position in SS, reflecting the difficulties in assessing asymmetry of the hindlimbs. It is unknown what degree of asymmetry is clinically relevant, suggesting that more consistent use in training horses may help determine the thresholds for asymmetry. Some degree of asymmetry may be clinically relevant, suggesting its regular use in training horses.
2024-01-01T00:00:00ZSemaglutide improves liver steatosis and de novo lipogenesis markers in obese and type-2-diabetic mice with metabolic-dysfunction-associated steatotic liver diseaseSoto-Catalán, ManuelOpazo-Ríos, LucasQuiceno, HernánLázaro, IolandaMoreno, Juan AntonioGómez-Guerrero, CarmenEgido, J.Mas-Fontao, Sebastiánhttp://hdl.handle.net/10396/276012024-03-05T03:01:12Z2024-01-01T00:00:00ZSemaglutide improves liver steatosis and de novo lipogenesis markers in obese and type-2-diabetic mice with metabolic-dysfunction-associated steatotic liver disease
Soto-Catalán, Manuel; Opazo-Ríos, Lucas; Quiceno, Hernán; Lázaro, Iolanda; Moreno, Juan Antonio; Gómez-Guerrero, Carmen; Egido, J.; Mas-Fontao, Sebastián
Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a prevalent clinical condition associated with elevated morbidity and mortality rates. Patients with MASLD treated with semaglutide, a glucagon-like peptide-1 receptor agonist, demonstrate improvement in terms of liver damage. However, the mechanisms underlaying this beneficial effect are not yet fully elucidated. We investigated the efficacy of semaglutide in halting MASLD progression using a genetic mouse model of diabesity. Leptin-receptor-deficient mice with obesity and diabetes (BKS db/db) were either untreated or administered with semaglutide for 11 weeks. Changes in food and water intake, body weight and glycemia were monitored throughout the study. Body fat composition was assessed by dual-energy X-ray absorptiometry. Upon sacrifice, serum biochemical parameters, liver morphology, lipidomic profile and liver-lipid-related pathways were evaluated. The semaglutide-treated mice exhibited lower levels of glycemia, body weight, serum markers of liver dysfunction and total and percentage of fat mass compared to untreated db/db mice without a significant reduction in food intake. Histologically, semaglutide reduced hepatic steatosis, hepatocellular ballooning and intrahepatic triglycerides. Furthermore, the treatment ameliorated the hepatic expression of de novo lipogenesis markers and modified lipid composition by increasing the amount of polyunsaturated fatty acids. The administration of semaglutide to leptin-receptor-deficient, hyperphagic and diabetic mice resulted in the amelioration of MASLD, likely independently of daily caloric intake, suggesting a direct effect of semaglutide on the liver through modulation of the lipid profile.
2024-01-01T00:00:00ZDoes telotristat have a role in preventing carcinoid heart disease?Herrera-Martínez, Aura D.Fuentes-Fayos, Antonio C.Sánchez-Sánchez, RafaelMontero-Hidalgo, Antonio J .Sarmento-Cabral, AndréGálvez-Moreno, M. ÁngelesGahete Ortiz, Manuel D.Luque, Raúl M.http://hdl.handle.net/10396/274492024-02-14T03:01:11Z2024-01-01T00:00:00ZDoes telotristat have a role in preventing carcinoid heart disease?
Herrera-Martínez, Aura D.; Fuentes-Fayos, Antonio C.; Sánchez-Sánchez, Rafael; Montero-Hidalgo, Antonio J .; Sarmento-Cabral, André; Gálvez-Moreno, M. Ángeles; Gahete Ortiz, Manuel D.; Luque, Raúl M.
Carcinoid heart disease (CHD) is a frequent and life-threatening complication in patients with carcinoid tumors. Its clinical management is challenging is some cases since serotonin-induced valve fibrosis leads to heart failure. Telotristat is an inhibitor of tryptophan-hydroxylase (TPH), a key enzyme in serotonin production. Telotristat use in patients with carcinoid syndrome and uncontrollable diarrhea under somatostatin analogs is approved, but its specific role in patients with CHD is still not clear. IN this context, we aimed to explore the effect of telotristat in heart fibrosis using a mouse model of serotonin-secreting metastasized neuroendocrine neoplasm (NEN). To this aim, four treatment groups (n = 10/group) were evaluated: control, monthly octreotide, telotristat alone, and telotristat combined with octreotide. Plasma serotonin and NT-proBNP levels were determined. Heart fibrosis was histologically evaluated after 6 weeks of treatment or when an individual mouse’s condition was close to being terminal. Heart fibrosis was observed in all groups. Non-significant reductions in primary tumor growth were observed in all of the treated groups. Feces volume was increased in all groups. A non-significant decrease in feces volume was observed in the octreotide or telotristat-treated groups, while it was significantly reduced with the combined treatment at the end of the study compared with octreotide (52 g reduction; p < 0.01) and the control (44.5 g reduction; p = 0.05). Additionally, plasma NT-proBNP decreased in a non-significant, but clinically relevant, manner in the octreotide (28.2% reduction), telotristat (45.9% reduction), and the octreotide + telotristat (54.1% reduction) treatment groups. No significant changes were observed in plasma serotonin levels. A similar non-significant decrease in heart valve fibrosis was observed in the three treated groups. In conclusion, Telotristat alone and especially in combination with octreotide decreases NT-proBNP levels in a mouse model of serotonin-secreting metastasized NEN, when compared with the control and octreotide, but its effect on heart valve fibrosis (alone and in combination) was not superior to octreotide in monotherapy.
2024-01-01T00:00:00ZNutritional, hormonal, and depot-dependent regulation of the expression of the small GTPase Rab18 in rodent adipose tissuePulido, Marina R.Rabanal Ruiz, YoanaAlmabouada, FaridDíaz-Ruiz, AlbertoBurrel, María AVázquez, María J.Castaño, Justo P.Kineman, Rhonda D.Luque, Raúl M.Diéguez, CarlosVázquez-Martínez, RafaelMalagón, María M.http://hdl.handle.net/10396/268042024-01-27T03:00:55Z2013-01-01T00:00:00ZNutritional, hormonal, and depot-dependent regulation of the expression of the small GTPase Rab18 in rodent adipose tissue
Pulido, Marina R.; Rabanal Ruiz, Yoana; Almabouada, Farid; Díaz-Ruiz, Alberto; Burrel, María A; Vázquez, María J.; Castaño, Justo P.; Kineman, Rhonda D.; Luque, Raúl M.; Diéguez, Carlos; Vázquez-Martínez, Rafael; Malagón, María M.
There is increasing evidence that proteins associated with lipid droplets (LDs) play a key role in the coordination of lipid storage and mobilization in adipocytes. The small GTPase, RAB18, has been recently identified as a novel component of the protein coat of LDs and proposed to play a role in both β-adrenergic stimulation of lipolysis and insulin-induced lipogenesis in 3T3-L1 adipocytes. In order to better understand the role of Rab18 in the regulation of lipid metabolism in adipocytes, we evaluated the effects of age, fat location, metabolic status, and hormonal milieu on Rab18 expression in rodent white adipose tissue (WAT). Rab18 mRNA was undetectable at postnatal day 15 (P15), but reached adult levels by P45, in both male and female rats. In adult rats, Rab18 immunolocalized around LDs, as well as within the cytoplasm of mature adipocytes. A weak Rab18 signal was also detected in the stromal-vascular fraction of WAT. In mice, fasting significantly increased, though with a distinct time-course pattern, Rab18 mRNA and protein levels in visceral and subcutaneous WAT. The expression of Rab18 was also increased in visceral and subcutaneous WAT of obese mice (diet-induced, ob/ob, and New Zealand obese mice) compared with lean controls. Rab18 expression in rats was unaltered by castration, adrenalectomy, or GH deficiency but was increased by hypophysectomy, as well as hypothyroidism. When viewed together, our results suggest the participation of Rab18 in the regulation of lipid processing in adipose tissue under both normal and pathological conditions
2013-01-01T00:00:00Z